RIXPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
RIXPHARMA
Largest movements
- Cash -€243,420
down €243,420 (-68.0%), from €357,920 to €114,500
mainly Other debts (-€200,000) and Current investments (-€38,557)
- Current investments +€38,557
new in 2025: €38,557
- Other debts -€200,000
down €200,000 (-81.7%), from €244,887 to €44,887
- Profit (loss) carried forward -€5,655
down €5,655 (-250.8%), from -€2,254 to -€7,910
- Gross operating margin -€1,999
down €1,999 (-61.4%), from -€3,256 to -€5,255
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €357,920 | €153,057 | -€204,863 | -57.2% |
| Current assets | 29/58 | €357,920 | €153,057 | -€204,863 | -57.2% |
| Current investments | 50/53 | - | €38,557 | +€38,557 | |
| Cash at bank and in hand | 54/58 | €357,920 | €114,500 | -€243,420 | -68.0% |
| Total equity and liabilities | 10/49 | €357,920 | €153,057 | -€204,863 | -57.2% |
| Equity | 10/15 | €113,032 | €107,377 | -€5,655 | -5.0% |
| Contributions | 10/11 | €96,200 | €96,200 | = | 0.0% |
| Reserves | 13 | €19,087 | €19,087 | = | 0.0% |
| Distributable reserves | 133 | €19,087 | €19,087 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€2,254 | -€7,910 | -€5,655 | -250.8% |
| Amounts payable | 17/49 | €244,887 | €45,679 | -€199,208 | -81.3% |
| Amounts payable within one year | 42/48 | €244,887 | €45,679 | -€199,208 | -81.3% |
| Trade debts | 44 | - | €792 | +€792 | |
| Suppliers | 440/4 | - | €792 | +€792 | |
| Other amounts payable | 47/48 | €244,887 | €44,887 | -€200,000 | -81.7% |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | -€3,256 | -€5,255 | -€1,999 | -61.4% |
| Operating profit (loss) | 9901 | -€3,644 | -€5,655 | -€2,011 | -55.2% |
| Financial income | 75/76B | €0 | €0 | -€0 | -100.0% |
| Recurring financial income | 75 | €0 | €0 | -€0 | -100.0% |
| Profit (loss) for the period before taxes | 9903 | -€3,643 | -€5,655 | -€2,012 | -55.2% |
| Profit (loss) for the period | 9904 | -€3,643 | -€5,655 | -€2,012 | -55.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,643 | -€5,655 | -€2,012 | -55.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.